The Scottish Medicines Consortium (SMC) has announced their latest set of recommendations approving regulatory submissions for Novartis and ThromboGenics’ eye therapy Jetrea and Roche’s RoActemra. The SMC have also announced rejections for the chronic obstructive pulmonary disease (COPD) drugs submitted for approval by Boehringer Ingelheim and GlaxoSmithKline (GSK).
Novartis’ Alcon unit has released Jetrea in the UK, its first market. The launch is under a month after European Commission approved Jetrea for the treatment of vitreomacular traction. Vitreomacular traction (VMT) is an age-related progressive, sight-threatening condition. Jetrea was approved for VMT, including when associated with macular hole of diameter less than or equal
Sweden’s BioInvent International has announced that they have been forced to restructure after the failure of an investigational antithrombotic in a mid-stage trial earlier this month. The corporation will restructure to have 68 permanent workers, in comparison to the present 89 permanent employee. The reduction of the staff “and other reprioritisations” will create cost savings
